Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-2575 in Relapsed or Refractory CLL and NHL
NCT03913949Phase 1Active, not recruiting
- Sponsor
- Ascentage Pharma
- Start
- Jun 2019
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lisaftoclax in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), sponsored by Ascentage Pharma. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jun 2019; status: active, not recruiting.
02
Drugs
lisaftoclax
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03913949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913949.